Chief Medical Officer · Structure Therapeutics Inc. (GPCR)

Mark Bach

A named executive officer of Structure Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$672,057

Salary $485,812Stock awards $0

FY2022: $628,374

3rd of 3 named executive officers at Structure Therapeutics by FY2023 total.

3 named officers on file for Structure Therapeutics, FY2023

Mark Bach’s pay file — $29

  • 2 fiscal years of pay, line by line
  • GPCR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Structure Therapeutics’s whole pay program stands against its peers

  • Structure Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GPCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A).

Free

Get Mark Bach’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Bach compensation by year

Structure Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Structure Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$466,375$485,812
Bonus$0$0
Stock awards$0$0
Option awards$0$0
Non-equity incentive$149,499$173,045
Pension and deferred compensation$0$0
All other$12,500$13,200
Total$628,374$672,057

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Structure Therapeutics Inc. DEF 14A filed April 25, 2024, accession 0001104659-24-051972, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Structure Therapeutics Inc. filed document, accession 0001104659-24-051972. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

$628K
$672K
FY22
FY23
SalaryNon-equity incentiveAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option218,124—$1.21
Option450,000—$5.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Structure Therapeutics Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Structure Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Raymond StevensChief Executive Officer and Director$7,390,911
Jun YoonChief Financial Officer$3,674,770
Mark Bach · this pageChief Medical Officer$672,057

The full Structure Therapeutics compensation record

free company brief

This page is one person within Structure Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Structure Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Structure Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Bach's compensation dossier · One-time report. No refunds.